Stemline Therapeutics (NASDAQ:STML) Stock Rating Reaffirmed by Cowen

Share on StockTwits

Stemline Therapeutics (NASDAQ:STML)‘s stock had its “buy” rating reissued by analysts at Cowen in a research report issued on Wednesday, AnalystRatings.com reports.

A number of other brokerages also recently weighed in on STML. ValuEngine downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, September 11th. Wedbush raised shares of Stemline Therapeutics from a “neutral” rating to an “outperform” rating in a research note on Friday, August 2nd. HC Wainwright set a $35.00 target price on shares of Stemline Therapeutics and gave the stock a “buy” rating in a research note on Thursday, June 20th. Roth Capital reaffirmed a “buy” rating on shares of Stemline Therapeutics in a research note on Thursday, May 23rd. Finally, Zacks Investment Research downgraded shares of Stemline Therapeutics from a “buy” rating to a “hold” rating in a research note on Wednesday, August 7th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $23.50.

Shares of NASDAQ STML opened at $11.25 on Wednesday. Stemline Therapeutics has a 1-year low of $7.82 and a 1-year high of $18.22. The company has a market cap of $480.43 million, a PE ratio of -3.76 and a beta of 1.39. The company has a current ratio of 4.71, a quick ratio of 4.57 and a debt-to-equity ratio of 0.01. The company has a 50-day moving average of $13.15 and a two-hundred day moving average of $13.73.

Stemline Therapeutics (NASDAQ:STML) last announced its earnings results on Friday, August 2nd. The biopharmaceutical company reported ($0.42) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.47) by $0.05. The company had revenue of $13.01 million during the quarter, compared to the consensus estimate of $8.84 million. As a group, equities research analysts forecast that Stemline Therapeutics will post -1.98 earnings per share for the current year.

In other news, CEO Ivan Bergstein sold 56,316 shares of Stemline Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The shares were sold at an average price of $15.08, for a total transaction of $849,245.28. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, COO Kenneth Hoberman sold 47,115 shares of Stemline Therapeutics stock in a transaction that occurred on Wednesday, June 26th. The stock was sold at an average price of $15.07, for a total transaction of $710,023.05. The disclosure for this sale can be found here. In the last quarter, insiders have sold 158,370 shares of company stock valued at $2,383,666. 13.10% of the stock is owned by corporate insiders.

Several large investors have recently modified their holdings of the company. Nuveen Asset Management LLC acquired a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $1,968,000. OneAscent Financial Services LLC acquired a new stake in shares of Stemline Therapeutics during the 2nd quarter worth approximately $175,000. Citadel Advisors LLC grew its position in shares of Stemline Therapeutics by 2,681.4% during the 2nd quarter. Citadel Advisors LLC now owns 357,411 shares of the biopharmaceutical company’s stock worth $5,476,000 after buying an additional 344,561 shares during the period. Point72 Asset Management L.P. grew its position in shares of Stemline Therapeutics by 196.5% during the 2nd quarter. Point72 Asset Management L.P. now owns 518,870 shares of the biopharmaceutical company’s stock worth $7,949,000 after buying an additional 343,870 shares during the period. Finally, Vanguard Group Inc. grew its position in shares of Stemline Therapeutics by 14.0% during the 2nd quarter. Vanguard Group Inc. now owns 1,933,455 shares of the biopharmaceutical company’s stock worth $29,620,000 after buying an additional 237,768 shares during the period. Institutional investors own 82.46% of the company’s stock.

About Stemline Therapeutics

Stemline Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of oncology therapeutics in the United States and internationally. The company offers ELZONRIS, a targeted therapy directed to the interleukin-3 receptor (CD123) for patients with blastic plasmacytoid dendritic cell neoplasm in adults, and in pediatric patients two years and older.

Featured Article: What are no-load funds?

Analyst Recommendations for Stemline Therapeutics (NASDAQ:STML)

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Preferred Apartment Communities Inc.  Short Interest Down 17.4% in September
Preferred Apartment Communities Inc. Short Interest Down 17.4% in September
Flexible Solutions International  Shares Cross Above 200 Day Moving Average of $3.02
Flexible Solutions International Shares Cross Above 200 Day Moving Average of $3.02
Laurentian Bank of Canada  Stock Passes Above 200-Day Moving Average of $43.78
Laurentian Bank of Canada Stock Passes Above 200-Day Moving Average of $43.78
Shaftesbury  Shares Pass Above Two Hundred Day Moving Average of $840.61
Shaftesbury Shares Pass Above Two Hundred Day Moving Average of $840.61
High Liner Foods  Share Price Crosses Above 200 Day Moving Average of $9.50
High Liner Foods Share Price Crosses Above 200 Day Moving Average of $9.50
Aspen Aerogels Inc  Short Interest Up 12.4% in September
Aspen Aerogels Inc Short Interest Up 12.4% in September


© 2006-2019 Ticker Report